lebrikizumab
mAbapprovedFast Track FDA
Approved
Sep 13, 2024
Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis. It is an interleukin-13 antagonist. It is given by subcutaneous injection. — Wikipedia
Clinical trial activity
45 trials · 9 clinical orgs · 1 marketing orgs
Phase 1
6
Phase 2
38
Phase 3
25
Phase 4
2
Earliest trial started May 1, 2006 (NCT00441818)
Timeline
Indications
Studied for
- Asthma · Phase 3
- Dermatitis · Phase 3
- Dermatitis, Atopic · Phase 4
- Eczema · Phase 3
- Healthy Volunteers · Phase 1
- Hodgkin Disease · Phase 1/Phase 2
- Idiopathic Pulmonary Fibrosis · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 2
- Rhinitis, Allergic, Perennial · Phase 3
- Sinusitis · Phase 3
- Skin Diseases · Phase 3
- Skin Diseases, Genetic · Phase 3
Mechanism of action
- Interleukin-13INHIBITOR
IL13 inhibitor
Approval history
- approvedFast trackSep 13, 2024
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaLebrikizumab ↗
- ChEMBLCHEMBL2109466 ↗
- ChEMBLCHEMBL1743035 ↗
Also known as
- lebrikizumab
- lebrikizumab
- lebrikizumab
- milr1444a
- pro-301444
- pro-301444 rg-3637
- rg-3637
- tnx-650
- tnx-650
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06906497 | Phase 4 | Jul 2, 2025 | Almirall, Dermira, Inc., University of Michigan |
| NCT07006792 | Phase 4 | Jun 16, 2025 | Eli Lilly |
| NCT06921759 | Phase 3 | Apr 21, 2025 | Eli Lilly |
| NCT06526182 | Phase 3 | Jul 3, 2024 | Almirall |
| NCT06444165 | Phase 3 | Jun 4, 2024 | Eli Lilly |
| NCT06338995 | Phase 3 | Apr 29, 2024 | Eli Lilly |
| NCT06339008 | Phase 3 | Apr 26, 2024 | Eli Lilly |
| NCT06280716 | Phase 3 | Apr 24, 2024 | Eli Lilly |
| NCT06243198 | Phase 1 | Mar 28, 2024 | Eli Lilly |
| NCT06119529 | Phase 1 | Nov 1, 2023 | Eli Lilly |
| NCT05990725 | Phase 3 | Oct 30, 2023 | Almirall |
| NCT05916365 | Phase 3 | May 23, 2023 | Almirall |
| NCT05735483 | Phase 3 | Mar 9, 2023 | Eli Lilly |
| NCT05369403 | Phase 3 | Dec 19, 2022 | Eli Lilly |
| NCT05372419 | Phase 3 | Dec 15, 2022 | Eli Lilly |
| NCT05559359 | Phase 3 | Oct 18, 2022 | Dermira, Inc., Eli Lilly |
| NCT05149313 | Phase 3 | Dec 31, 2021 | Almirall |
| NCT04840901 | Phase 1 | Jun 2, 2021 | Eli Lilly |
| NCT04760314 | Phase 3 | Mar 10, 2021 | Eli Lilly |
| NCT04626297 | Phase 3 | Nov 17, 2020 | Eli Lilly |
Showing 20 of 45 trials
Page 1 / 3
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 16 | 15 | 3 | 2020 |
| Roche | For profit | 12 | 11 | 3 | 2013 |
| Dermira, Inc. | For profit | 8 | 6 | 3 | 2018 |
| Genentech | For profit | 7 | 7 | 2 | 2008 |
| Almirall | For profit | 5 | 4 | 2 | 2021 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Tanox | For profit | 1 | 1 | 1 | 2006 |
| University of Michigan | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2006 |
9 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eli Lilly | For profit | NDA | Sep 13, 2024 |